Steven A. Feldman
Impact in
- Oncology top 0.05%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 64
- CAR-T cell therapy research 63
- Cancer Immunotherapy and Biomarkers 6
- Immunology 30
- Immunotherapy and Immune Responses 22
- Immune Cell Function and Interaction 13
- Co-authors
- Steven A. Rosenberg (45 shared papers)James N. Kochenderfer (24 shared papers)Maryalice Stetler‐Stevenson (8 shared papers)Richard A. Morgan (10 shared papers)Mark E. Dudley (14 shared papers)Irina Marić (7 shared papers)Richard M. Sherry (13 shared papers)Wyndham H. Wilson (5 shared papers)
- Journals
- Blood (14 papers)Journal of Clinical Oncology (7 papers)Journal of Immunotherapy (6 papers)Journal of Virology (5 papers)Molecular Therapy (5 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Steven A. Feldman
85 papers receiving 11.9k citations
Steven A. Feldman's Hit Papers
Peers
Comparison fields: 5 of 123
- Oncology 9.8k
- Immunology 4.4k
- Genetics 2.8k
- Hematology 697
- Biomedical Engineering 2.2k
Countries citing papers authored by Steven A. Feldman
This map shows the geographic impact of Steven A. Feldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven A. Feldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven A. Feldman more than expected).
Fields of papers citing papers by Steven A. Feldman
This network shows the impact of papers produced by Steven A. Feldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven A. Feldman. The network helps show where Steven A. Feldman may publish in the future.
Co-authors
The 25 scholars most cited alongside Steven A. Feldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Hit paper breakdown → | 2014 | 2181 |
| 2 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells Hit paper breakdown → | 2011 | 1140 |
| 3 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Hit paper breakdown → | 2010 | 1045 |
| 4 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Hit paper breakdown → | 2010 | 798 |
| 5 | T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma Hit paper breakdown → | 2016 | 605 |
| 6 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response Hit paper breakdown → | 2014 | 598 |
| 7 | T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma Hit paper breakdown → | 2018 | 569 |
| 8 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer Hit paper breakdown → | 2018 | 554 |
| 9 | Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma Hit paper breakdown → | 2015 | 343 |
| 10 | 2009 | 318 | |
| 11 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma Hit paper breakdown → | 2019 | 311 |
| 12 | 2008 | 255 | |
| 13 | 2012 | 246 | |
| 14 | 2000 | 225 | |
| 15 | 2017 | 209 | |
| 16 | 2010 | 208 | |
| 17 | 2017 | 205 | |
| 18 | Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Hit paper breakdown → | 2021 | 199 |
| 19 | 1999 | 194 | |
| 20 | 2017 | 165 |
About Steven A. Feldman
Steven A. Feldman is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Biomedical Engineering, having authored 87 papers that have together received 12.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (63 papers), Immunotherapy and Immune Responses (22 papers), Virus-based gene therapy research (22 papers), Viral Infectious Diseases and Gene Expression in Insects (14 papers), Immune Cell Function and Interaction (13 papers), Cancer Immunotherapy and Biomarkers (6 papers), Nanowire Synthesis and Applications (4 papers) and Respiratory viral infections research (4 papers). The work is most often cited by research in Oncology (9.8k citations), Immunology (4.4k citations), Genetics (2.8k citations), Hematology (697 citations) and Biomedical Engineering (2.2k citations). Steven A. Feldman has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Steven A. Rosenberg, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Richard A. Morgan, Mark E. Dudley, Irina Marić, Richard M. Sherry, Wyndham H. Wilson, James C. Yang and Udai S. Kammula. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Immunotherapy, Journal of Virology and Molecular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.